Fluorogenic Coupled Assays Reveal Catalytic Properties, Inhibition Constants and Cellular Location of Mucin‐Active Carbohydrate Sulfatases Authors: Charles W E Tomlinson, Madouc D Bergers, David N Bolam, Ana S Luis, Alan Cartmell, Zachary Armstrong Published: 2026 ABSTRACT ABSTRACTSulfated glycans play a central role in human health and influence cell signaling, cancer progression, pathogen invasion, and host‐microbiome interactions. Metabolism of these glycans requires a specialized class of enzymes termed carbohydrate sulfatases. These enzymes are particularly important in the human gut where sulfated colonic mucin is produced and subsequently degraded by colonic bacteria. Despite the biological importance of carbohydrate sulfatases, there is currently a lack of chemical tools to study their activity, substrate selectivity, inhibition, and the discovery of novel enzymes. To address this, we have synthesized new chemical tools to rapidly and quantitatively determine the activity and selectivity of carbohydrate sulfatases in plate‐based coupled assays. We have synthesized 3‐O‐sulfated fluorogenic glycosides using efficient synthetic routes and combined these fluorogenic substrates with a glycosidase that selectively cleaves unsulfated glycosides, allowing sensitive detection of sulfatase activity on both purified protein and cell lysate from the S1_20 subfamily sulfatases. Furthermore, we show that the assay enables differentiation and quantification of substrate specificity, identification of sulfatase inhibitors, and determination of sulfatase (sub‐)cellular location for two S1_20 subfamily sulfatases. Collectively, we anticipate that these tools will further our understanding of the interplay between carbohydrate sulfatases, sulfated glycans, and human health.Keywords: biochemistry, carbohydrate, glycan, mucin, sialidase, sulfatase, sulfation Introduction Sulfated glycans are found at the surfaces of human cells, on proteoglycans in the extracellular matrix, and on secreted proteins, such as mucins present in the gut [1, 2, 3]. Turnover or degradation of these glycans requires a specialized class of enzymes termed carbohydrate sulfatases. These enzymes are particularly important in the gut where sulfated colonic mucin is produced by humans, and it is degraded by bacterial members of the colonic microbiota [4, 5]. This relationship is usually symbiotic, however, depletion of the colonic mucin by bacteria can lead to inflammatory bowel diseases and bacterial carbohydrate sulfatases have been implicated in these diseases [6, 7]. Furthermore, recent work has highlighted the importance of bacterial carbohydrate sulfatases for the colonic mucin‐degrading bacterium, Bacteroides thetaiotaomicron VPI‐5482 (B. theta), to utilize heavily sulfated colonic mucin [4, 5]. Notably, a single extracellular sulfatase (BT16363S‐Gal from the S1_20 subfamily) was essential to adequately metabolise sulfated mucin O‐glycans in vitro, and for competitive colonization in germ‐free mice [5]. Sulfatase sequences are classified into four families (S1–S4) and catalogued on the SulfAtlas database [8, 9]. Carbohydrate sulfatases are currently only found in the S1 family which comprises over 90% of all known sulfatase sequences. The S1 family is grouped into 110 subfamilies (denoted S1_X) based on sequence homology. This family of sulfatases employs a non‐genome encoded amino acid, formylglycine (FGly), generated from a Ser or Cys in the consensus sequence C/S‐X‐P/A‐X‐R, as their catalytic nucleophile and a His or Lys as their catalytic acid. S1 carbohydrate sulfatases are thought to hydrolyze sulfate esters via a transesterification‐elimination mechanism [10] (Figure 1A). Sulfatase mechanism and coupled assay development. (A) S1 carbohydrate sulfatases employ an active site formylglycine to catalyse sulfate hydrolysis. The reaction mechanism is proposed to proceed through a transesterification‐elimination mechanism, that involves initial attack of the sulfate ester by the hydrated formylglycine. This leads to a covalent sulfated‐enzyme intermediate that can then undergo elimination, thereby releasing the sulfate and regenerating the formylglycine residue. This residue is then hydrated to restore the catalytic nucleophile. (B) Conceptual design of fluorogenic coupled assays to detect sulfatase activity. A sulfated carbohydrate bearing a fluorogenic group (here 4‐methylumbelliferone) linked at the anomeric position is incubated with a mixture of a carbohydrate sulfatase and a glycosidase. It is essential that the glycosidase can only cleave the desulfated glycoside, and not the sulfated glycoside. Fluorophore release directly reports the sulfatase hydrolysis rate, under conditions where the glycosidase is nonrate‐limiting. This assay can be used to detect both the presence of a carbohydrate sulfatase, and the decrease in activity due to the presence of an inhibitor. (C) Sulfated fluorogenic glycosides synthesized herein and employed in coupled assays. Several challenges are faced when characterizing S1 carbohydrate sulfatases. S1 sulfatases that act on arylsulfates, such as those acting on sulfated steroids [11], can be rapidly detected using aromatic, sulfated fluorogenic and chromogenic compounds [12]. However, this is not the case for many S1 carbohydrate sulfatases because these enzymes do not readily hydrolyze sulfated aromatics [13]. Alternative methods, such as detecting the pH change as sulfate groups are released, are time consuming, relatively insensitive, difficult to measure, and often low‐throughput [14]. Turbidity measurements using barium are insensitive and slow [15] and a capillary electrophoresis method linked to fluorescence detection, developed using a Perkin Elmer EZreaderII, is no longer commercially available and required expensive consumables [16]. Additionally, qualitative assays such as thin layer chromatography (TLC) and high‐performance anion exchange chromatography (HPAEC) appear to show incomplete substrate hydrolysis at the high concentrations of substrate used [4]. Coupled assays, employing a sulfated fluorogenic substrate and a glycosidase that can cleave the desulfated glycoside have previously been developed for select carbohydrate sulfatases [17, 18, 19, 20, 21, 22], however these methods have not yet been developed for S1_20 sulfatases. Thus, there is a need for fast, sensitive, facile, and high‐throughput technologies to assess S1_20 carbohydrate sulfatase activity. We describe the development of a fluorescent assay for the rapid determination of carbohydrate sulfatase activity. This assay employs a sulfated carbohydrate (galactose or N‐acetylgalactosamine here) linked to a fluorogenic aglycone (Figure 1B). When the sulfated reporter is cleaved by the requisite sulfatase, a desulfated fluorogenic carbohydrate is released. This fluorogenic carbohydrate can then be cleaved by a complementary glycosidase that is unreactive toward the sulfated substrate. Here, we have used this coupled assay method to interrogate S1_20 sulfatases from the human symbiont Bacteroides thetaiotaomicron. We have synthesized 4‐methylumbelliferyl 3‐O‐sulfo‐β‐D‐galactopyranoside (MU‐β‐3S‐Gal, 1), 4‐methylumbelliferyl 3‐O‐sulfo‐N‐acetyl‐β‐D‐galactopyranosaminide (MU‐β‐3S‐GalNAc, 2) and 4‐methylumbelliferyl 3‐O‐sulfo‐N‐acetyl‐α‐D‐galactopyranosaminide (MU‐α‐3S‐GalNAc, 3), see Figure 1C, as reporter molecules for S1_20 sulfatases. Using a coupled assay with β‐D‐galactosidase or N‐acetyl α‐/β‐D‐galactosaminidase, the synthesized substrates enable detection of S1_20 sulfatase activity in a 96‐well plate format via fluorescence readout. We use these substrates to determine Michaelis–Menten parameters for BT16363S‐Gal and its homologue BT16223S‐GalNAc/Gal, demonstrating vastly different K M values, as well as inhibition by different inorganic oxo‐anions and aluminum fluoride. We further use these substrates to demonstrate the cellular location of BT16363S‐Gal from cells in media. This demonstrates how sulfated, fluorescent glycosides, linked to an appropriate glycosidase, can be used to determine the biochemical properties and cellular location of carbohydrate sulfatases. Results and Discussion Expedient Synthesis of 4‐methylumbelliferyl‐3‐O‐sulfo‐glycosides Although MU‐Gal is commercially available, we deemed this to be prohibitively expensive as a starting point for the synthesis of MU‐β‐3S‐Gal (1). We therefore commenced our synthetic route from the commercially available β‐D‐galactose pentaacetate (4) (Scheme 1A). Treatment of 4 with HBr in acetic acid furnished the corresponding α‐galactosyl bromide, which was coupled with 4‐methylumbelliferone under phase transfer conditions to afford peracetylated MU‐β‐galactoside 5 in a 79% yield over two steps. Zemplén deacetylation, followed by a regio‐selective 3‐O‐sulfation of the resulting unprotected MU‐Gal 6, afforded MU‐3S‐Gal (1) [23, 24]. The regio‐selective sulfation was achieved by activating the 3‐OH through formation of a stannylene acetal bridging the cis‐diol, followed by treatment with SO3·Et3N. MU‐β‐3S‐GalNAc (2) was synthesized using a similar methodology (Scheme 1A). Peracetylated galactosamine 7 was converted into the corresponding anomeric chloride using HCl in AcCl, followed by a substitution with 4‐methylumbelliferone to afford fully protected β‐galactoside 8 (35% over two steps), according to literature precedent [25, 26]. Zemplén deacetylation, followed by a regio‐selective sulfation of unprotected MU GalNAc 9, using the same stannylene acetal chemistry as used for its Gal equivalent 1, furnished MU‐β‐3S‐GalNAc 2 23. Synthesis of sulfated MU glycosides 1–3. Reagents and conditions: A. (a) i. 33 wt. % HBr in AcOH, DCM, 0°C; ii. tetrabutylammonium hydrogen sulfate, NaOH, 4‐methylumbelliferone, DCM/H2O (3:2 v/v), rt, (5: 79% over two steps); (b) i. 4 M HCl in dioxane, AcCl, 40°C; ii. tetrabutylammonium bromide, CsOH, 4‐methylumbelliferone, DCM/H2O (3:2 v/v), rt, (8: 35% over two steps); (c) NaOMe, MeOH, rt (6: 84%, 9: 85%); (d) i. Bu2SnO, DMF/toluene (1:2 v/v), reflux; ii. SO3·Et3N, DMF, rt (1: 51% over two steps, 2: 15% over two steps); B. (e) Ac2O, pyridine, 0°C to rt, (96%); (f) NIS, acetone/H2O (1:1 v/v), rt (88%); (g) 2,2,2‐trifluoro‐N‐phenylacetimidoyl chloride, Cs2CO3, acetone/water (50:1 v/v), 0°C → rt (97%); (h) 4‐methylumbelliferone, TMSOTf, DCM, −25°C to rt (67%); (i) i. H2, PtO2, THF, rt; ii. Ac2O, pyridine, 0°C → rt (85% over 2 steps); (j) NaOMe, MeOH, rt (86%); (k) SO3·pyridine, DMF, rt (90%); (l) 70% w/w HF‐pyridine, pyridine, 0°C to rt, (86%). For the introduction of the challenging α‐aryl glycosidic linkage in MU‐α‐3S‐GalNAc (3), we opted to use a di‐tert‐butylsilylidene (DTBS)‐functionalized donor (Scheme 1B). This glycosylation strategy, originally developed by Kiso and coworkers, is one of the most powerful methods to introduce 1,2‐cis linkages, and can even override neighboring group participation [27, 28]. Additionally, protection of the 3‐position with an orthogonal protecting group enables selective unmasking of this hydroxyl group for late‐stage sulfation. Therefore, the synthesis of MU‐α‐3S‐GalNAc (3) commenced with the acetylation of DTBS protected galactoside 10, which was synthesized from commercially available tri‐O‐acetyl‐D‐galactal, using literature precedent [29, 30] (Scheme 1B). The anomeric selenoacetal of galactoside 12 was hydrolyzed using NIS in aqueous acetone to obtain hemiacetal 13 in 88% yield. Subsequently, trifluoroimidate 14 was synthesized by treatment of 13 with 2,2,2‐trifluoro‐N‐phenylacetimidoyl chloride and a mild base (97% yield) [31]. The resulting imidate donor 14 was immediately subjected to a TMSOTf‐promoted glycosylation to exclusively yield the α‐anomer 15 in a 67% yield. Azide 15 was reduced to the free amine using a Pt‐catalyzed hydrogenation, followed by acetylation using Ac2O to afford fully protected MU‐α‐GalNAc 16 in 85% over two steps. Deprotection of the acetyl group under Zémplen conditions resulted in alcohol 17 (86% yield), which was subjected to SO3·pyridine in DMF to afford 3S‐galactoside 18 (90% yield). Desilylation using HF‐pyridine resulted in MU‐α‐3S‐GalNAc (3) in an 86% yield. S1_20 Enzymes Have Different Affinities for 3‐O‐sulfo‐D‐galacto‐configured Substrates Despite the proposed role of BT16363S‐Gal as a critical, high‐affinity sulfatase in B. theta for colonic mucin metabolism, no absolute measure of affinity or catalytic turnover of the recombinant enzyme has been reported [5]. Catalytic constants were determined using a coupled assay that employs a GH2 β‐galactosidase BT0461GH2, that cleaves 4‐methylumbelliferyl β‐d‐galactopyranoside (MU‐β‐Gal), at a sufficient concentration to render the sulfatases rate‐limiting (Figure 2A). Importantly, this galactosidase does not cleave MU‐β‐3S‐Gal (1). Using this assay, we determined the catalytic parameters, K M, k cat app, and k cat app/K M, for BT16363S‐Gal and BT16223S‐GalNAc/Gal for the hydrolysis of MU‐β‐3S‐Gal (1). An apparent k cat is reported as the amount of active enzyme is uncertain, due to incomplete conversion of the catalytic residue to a formyl glycine, and the values reported here were calculated using the total protein concentration. BT16363S‐Gal displayed a K M of ∼30 µM and a k cat app of 0.048 s−1, providing a k cat app/K M of 1.61 × 103 s−1 M−1 (Figure 2B and Table 1). In contrast, individual kinetic constants could not be established for BT16223S‐GalNAc/Gal using MU‐β‐3S‐Gal (1) as the reaction rates did not reach saturation at the highest substrate concentration. Only a k cat app/K M of 4.62 × 10−1 s−1 M−1 could be established with a K M of more than 1 mM (Figure 2C and Table 1). Using coupled assays to determine S1_20 carbohydrate sulfatase kinetics. A. Determination that BT16363S‐Gal dependent sulfate hydrolysis is the rate limiting step for the coupled reaction. B. Michaelis–Menten kinetics for BT16363S‐Gal with 4‐methylumbelliferyl 3‐O‐sulfo‐β‐d‐galactoside (1). C. Michaelis–Menten kinetics for BT16223S‐GalNAc/Gal with 4‐methylumbelliferyl 3‐O‐sulfo‐β‐D‐galactoside (1). D. Determination that BT16223S‐GalNAc/Gal dependent sulfate hydrolysis is the rate limiting step for the coupled reaction. E. Michaelis–Menten kinetics for BT16223S‐GalNAc/Gal using 4‐methylumbelliferyl 3‐O‐sulfo‐N‐acetyl‐α‐D‐galactoside (3). F. Michaelis–Menten kinetics for BT16223S‐GalNAc/Gal using 4‐methylumbelliferyl 3‐O‐sulfo‐N‐acetyl‐β‐D‐galactoside (2). All assays were carried out in triplicate in 10 mM HEPES pH 7.5 and 150 mM NaCl. Lines of best fit to hyperbolic equations are shown in pink, and a line of best fit to a linear equation is shown in blue. G. Surface representations of BT16363S‐Gal and BT16223S‐GalNAc/Gal in complex with their substrates, right and left respectively, with them overlaid in the middle panel. TABLE 1Michaelis constants determined for the hydrolysis of sulfated glycosides.ProteinSubstrate k cat app sec−1 K M µM k cat app/K M sec−1M−1 BT1636S77C MU‐β‐3S‐Gal(4.9 ± 0.2) × 10−2 30 ± 4(1.6 ± 0.2) x 103 BT1622S75C MU‐β‐3S‐Gal—— (4.6 ± 0.1) x 10−1 BT1622S75C MU‐α‐3S‐GalNAc(5.0 ± 0.2) × 10−3 670 ± 80(7.5 ± 0.9)BT1622S75C MU‐β‐3S‐GalNAc(5.4 ± 0.2) × 10−3 50 ± 6(1.1 ± 0.1) x 102 Michaelis constants determined for the hydrolysis of sulfated glycosides. The low activity of BT16223S‐GalNAc/Gal against MU‐β‐3S‐Gal (1) is consistent with its reported preference of 3‐O‐sulfated N‐acetylgalactosamine (3S‐GalNAc) [5]. To more accurately assess the kinetic properties of BT16223S‐GalNAc/Gal, we repeated the experiment with MU‐β‐3S‐GalNAc (2) and MU‐α‐3S‐GalNAc (3). BT16223S‐GalNAc/Gal showed activity against both substrates but with a ∼14‐fold preference for MU‐β‐3S‐GalNAc (2) over MU‐α‐3S‐GalNAc (3), as determined from their respective k cat app/K M (Figure 2 E,F). The k cat app was similar for both substrates with the difference in activity mainly driven by the ∼12‐fold increase in K M for the MU‐α‐3S‐GalNAc (3) substrate. To detect the presence of produced MU‐β‐D‐GalNAc, we initially tested BVU_2198GH123, an N‐acetyl‐β‐d‐galactosaminidase [32], as a coupled enzyme. Unfortunately, BVU_2198GH123 had a small amount of activity on (1) (Figure S1). This necessitated the use of a different enzyme, BT4243GH109, that is active on both α‐ and β‐GalNAc and absolutely requires a free alcohol at the 3‐position for catalysis [33], to underpin the linked assay (Figure 2D). However, the activity from BVU_2198GH123 does highlight the possibility of using the chemical tools developed here, to identify glycosidases that are able to accommodate sulfated sugars. Indeed, recent studies have used a fluorogenic or chromogenic 6‐O‐sulfatated N‐acetylglucosaminide substrates to discover and characterize a 6‐sulfo‐N‐acetylglucosaminidases [34, 35]. Work by Loft et al. also used sulfated chromogenic β‐N‐acetylgalactosaminides and discovered fungal enzymes capable of cleaving the 3‐, 4‐, and 6‐O‐sulfated sugars [17]. The above data demonstrate that BT16363S‐Gal and BT16223S‐GalNAc/Gal have high and low affinities, respectively, for 3‐O‐sulfated D‐galactose. This is consistent with previous data, demonstrating that BT16363S‐Gal had a ∼10‐fold greater k cat app/K M against BODIPY labelled 3‐O‐sulfated D‐galactose than BT16223S‐GalNAc/Gal, with BT16223S‐GalNAc/Gal belonging to the subset of S1_20 sulfatases that are preferentially active on 3‐O‐sulfated‐N‐acetyl‐D‐galactosamine [5]. This preference for GalNAc displayed by BT16223S‐GalNAc/Gal was borne out using the MU‐β‐3S‐GalNAc (2) and MU‐α‐3S‐GalNAc (3) substrates. Although BT16223S‐GalNAc/Gal displayed a preference for MU‐β‐3S‐GalNAc (2), its ability to also cleave MU‐α‐3S‐GalNAc (3) at appreciable rates correlates with the more open active site surrounding its 0‐subsite, the region that accommodates the monosaccharide bearing the targeted sulfate, when compared to other sulfatases, such as BT16363S‐Gal (Figure 2G). These data demonstrate that the aryl‐linked sulfo‐sugar substrates can be used to determine kinetic constants for S1_20 sulfatases targeting 3S‐Gal and 3S‐GalNAc and can differentiate between enzymes with high and low Michaelis constants; thereby providing a rapid biochemical tool for distinguishing between S1_20 members targeting 3‐O‐sulfated d‐galactose and 3‐O‐sulfated N‐acetyl‐d‐galactosamine. Coupled Fluorogenic Sulfatase Assays Enable the Identification of Potent Inhibitors of S1_20 Sulfatases Given that BT16363S‐Gal and its orthologues in other Bacteroidota species are potential drug targets, we envisioned that the coupled fluorogenic sulfatase assays developed here could also be used to both identify and quantify inhibitors of this enzyme class. As a proof of principle, we evaluated whether several oxoanions and AlF3, known transition‐state mimics of sulfatases or phosphatases, could inactivate BT16363S‐Gal or BT16223S‐GalNAc/Gal. We rationalized that these species could inhibit the above enzymes, as vanadate is a known inhibitor of S1_11 carbohydrate sulfatases [16] and oxoanions have previously been reported as inhibitors of an aryl sulfatase [36]. Inhibition assays performed in the presence of the above species (Figure 3, Table 1) reveal that, indeed, vanadate can block the action of both BT16363S‐Gal and BT16223S‐GalNAc/Gal sulfatases with IC50 values of 2.6 ± 0.5 and 1.0 ± 0.5 µM, respectively. Furthermore, chromate and tungstate also showed inhibition against both enzymes, although to a lesser extent than vanadate. In contrast, molybdate only showed a small percentage of inhibition against BT16363S‐Gal at the highest concentrations (Figure 3D,E, Table 1). The trigonal planar compound AlF3, which has previously been shown to structurally mimic the transition‐state of phosphatases [37], did not appreciably inhibit either protein (Figure 3C,D,E, Table 1). Using these assays, we were also able to observe inhibition of BT16363S‐Gal by tungstate and vanadate, in whole cells at concentrations close to those described above, and without substantially affecting cell viability (Figure S2). Orthovanadate is a potent inhibitor of S1_20 carbohydrate sulfatases. A. Dose‐response curve for inhibition of BT16363S‐Gal by orthovanadate using 1 mM 1 as substrate. B. Dose‐response curve for inhibition of BT16223S‐GalNAc/Gal by orthovanadate using 1 mM of 1 as substrate. C. Dose‐response curves for the inhibition of BT16363S‐Gal or BT16223S‐GalNAc/Gal by metal complexes using 1 mM 1 or 2 (respectively) as substrate. All assays were carried out in triplicate in 10 mM HEPES pH 7.5 and 150 mM NaCl. D. Stick representation of 1HDH (orange) and 7OQD (aqua) structures, showing substrate sulphate (HDH—black) and 3‐O‐sulfo‐β‐D‐galactopyranose (7OQD—yellow) orientations. E. Stick representation of crystals structures (determined here) of BT1636 soaked with phosphate (PDBID: 9THU; two blue ions), chromate (PDBID: 9THV; green ion), and molybdate (PDBID: 9THW; pink ion) showing distinct inhibitor ion conformations. An additional benefit of being able to determine the Michaelis constant (K M), vide supra, with these coupled assays is that the K M can be used, alongside the IC50, and substrate concentration to calculate inhibition rate constants via the Cheng–Prusoff equation [38], (Table 1). Inhibition constants (KI ) of 0.34 ± 0.07 and 0.11 ± 0.02 µM were determined for orthovanadate inhibition of BT16363S‐Gal and BT16223S‐GalNAc/Gal, respectively. This is ∼1000‐fold lower than the 117.6 µM K I value of orthovanadate for the S1_11 sulfatase BT46566S‐GlcNAc/GlcNS that de‐sulfates 6‐O‐sulfated N‐acetyl‐d‐glucosamine and 6‐O‐sulfated N‐sulfo‐d‐glucosamine [16]. This suggests that, despite high structural similarity of the sulfate binding site, differences in inhibitor affinities do exist, which could be exploited to develop tailored inhibitors involving tetrahedral metal complexes. These data demonstrate not only the utility of these fluorogenic substrates, but also the importance of using an appropriate substrate when determining IC50 values, which are significantly affected by substrate concentration and the enzyme specific Michaelis‐constant (K M) for said substrate. To better understand how the above transition metal oxoanions inhibit S1_20 sulfatases, we determined crystal structures of BT16363S‐Gal in complex with chromate and molybdate, as well as inorganic phosphate (Figures 3 and S3 and Table 2). The three oxoanions all adopt product orientations with their tetrahedral configuration ‘inverted’ compared to that observed in the sulfated substrate (PDB: 7OQD), and free sulfate observed in the orthologue PaAsta (PDB: 1HDH). These complexes indicate that the oxoanion inhibitors chromate and molybdate mimic product complexes, thus working through a similar binding mode observed in product inhibition. Although we were unable to obtain a crystal structure of the bound ortho vanadate, we suspect the enhanced inhibition by ortho vanadate may be due to the metal oxoanion adopting a conformation more closely mimicking a substrate or through covalent inhibition. TABLE 2Inhibition constants determined for oxoanions and aluminum fluoride. BT1636S77C – 3SGalβMUBT1622S75C – 3SGalNAcβMUInhibitor IC50 (µM), [1] = 200 µM KI calc (µM) IC50 (µM), [2] = 400 µM KI calc (µM) VO4 2− 2.6 ± 0.50.34 ± 0.071.0 ± 0.50.11 ± 0.02 CrO4 2− 11 ± 41.5 ± 0.580 ± 809 ± 9 WO4 2− 2000 ± 1000300 ± 2001000 ± 400100 ± 40 MoO4 2− >2500NANANA AlF3 NANANANA Inhibition constants determined for oxoanions and aluminum fluoride. IC50 (µM), [1] = 200 µM IC50 (µM), [2] = 400 µM Determining the Cellular Location of BT16363S‐Gal From Cells in Media The cellular location of an enzyme can be as critical as its specificity in performing its biological function. Signal peptide prediction using computational tools, such as SignalP 6.0 [39] and psortb [40], are largely based on Escherichia coli annotations and the prediction of protein localisation in phyla such as Bacteroidota can be challenging. These tools can determine the presence of SPI or SPII signal peptides, with the latter resulting in a membrane anchored protein. This information alone is insufficient to definitively determine whether a protein is periplasmic or extracellular in Gram‐negative bacteria. Although SPI proteins are largely presumed to be periplasmic several reports have found them to be extracellular [41, 42], while proteins with an SPII signal peptide are membrane anchored [43] this anchoring can occur at the cell surface or in the periplasm. The gold standard for protein localization is to generate a specific antibody for the protein target and combine this with fluorescent microscopy, or protease protection assays and western blotting. Although these assays are specific, they are also expensive, time‐consuming, and antibody production can fail. Bacteroides species under aerobic conditions are metabolically inactive and the diffusion of the substrates developed here is limited and/or slow [44]. This implies that synthetic substrates such MU‐β‐3S‐Gal (1), and MU‐β‐3S‐GalNAc (2) could be used as a readout for cell surface activity. To investigate whether the above substrates could be used to determine subcellular enzyme location, we tested the ability of whole cells and sonicated lysates of wildtype B. theta and a Δbt1636 strain, grown on gastric mucin oligosaccharides (gMOs), to turnover MU‐β‐3S‐Gal (1) in the presence of BT0461GH2. Assays were conducted aerobically, in the cell growth media, using 200 µM of MU‐β‐3S‐Gal (1). Hydrolysis was detected for wildtype whole cells but not the Δbt1636 strain (Figure 4A). Sonicated lysates from wildtype cells also showed high activity, whilst the Δbt1636 strain showed no activity. These data are consistent with BT16363S‐Gal having both an extracellular and intracellular location. BT16363S‐Gal has previously been confirmed as having an extracellular location and although our data agrees with this conclusion, they also reveal that although ∼10% of BT16363S‐Gal is extracellular, 90% is intracellular (Figure 4A). BT16363S‐Gal has an SPI signal peptide thus the intracellular activity is deduced to be from enzyme located in the periplasm. The mechanism by which B. theta localises the SPI possessing BT16363S‐Gal to the cell surface is unknown. However, the GH33 sialidase, BT0455GH33, which also has an SPI signal peptide has also been reported to have both an extracellular and periplasmic location [45]. Determining sulfatase cellular location. A. Cell based assays conducted in minimal media using 200 µM 3‐O‐sulfated 4‐methylumbelliferone‐β‐d‐galactose with wildtype and Δbt1636 strains of B. thetaiotaomicron. B. Cell based assays conducted in minimal media using 200 µM 3‐O‐sulfated 4‐methylumbelliferyl‐β‐d‐N‐acetyl galactose with wildtype and Δbt1622, Δbt1622/1636/4683 strains of B. thetaiotaomicron. C. Thin layer chromatography (TLC) analysis of PBS washed cells and lysates incubated with 5 mM of the disaccharide uronic acid β1,4 4‐O‐sulfated D‐GalNAc. D. High performance anion exchange chromatography of PBS washed cells and lysates incubated with 100 µM of the disaccharide α‐Δ4,5‐uronic acid‐(1→3)‐4‐O‐sulfo‐d‐GalNAc. All quantitative assays were conducted in triplicate whilst TLC analysis was performed in duplicate. In panels A and B significance of p < 0.0001 is denoted by ‘****’. Although the use of a linked enzyme improved rates of glycoside hydrolysis, there was enough endogenous galactosidase activity both at the cell surface and from lysates that cleavage of MU‐Gal product occurred (Figure 4A). No activity was observed in the Δbt1636 strain demonstrating that the assay was reporting the activity of BT16363S‐Gal and not any other carbohydrate sulfatase, or a GH capable of hydrolysing MU‐β‐3S‐Gal (1) (Figure 4A). Using the substrate MU‐β‐3S‐GalNAc (2) at 400 µM, and a similar method as above, we attempted to determine the cellular location of BT16223S‐GalNAc/Gal. Similar activity was detected as observed for BT16363S‐Gal, indicating the presence of activity at the cell surface but with greater activity observed from cell lysates (Figure 4B). This activity, however, was not lost when the cellular assays were repeated with the Δbt1622 strain, or the triple mutant Δbt1622/Δbt1636/Δbt4683 which is devoid of all 3S‐galacto‐targeting sulfatases (Figure 4B). This suggests there is either an unknown 3S‐GalNAc targeting sulfatase or a GH capable of hydrolysing MU‐β‐3S‐GalNAc (2). Identification of the enzyme responsible for this activity and whether it is a sulfatase from a different subfamily or a GH remains a question for future study. As cross validation of our cell‐based strategy above, we confirmed the location of the GAG targeting sulfatase BT33494S‐UA‐4SGalNAc, an enzyme known to be periplasmic [44]. Qualitative thin layer chromatography analysis, using 5 mM of the substrate Δ4,5‐uronic acid‐(1→3)‐4‐O‐sulfo‐d‐GalNAc (UA‐4SGalNAc), showed no hydrolysis of the substrate by whole cells after an incubation time of 1 and 16 h (Figure 4C). We then conducted the assay quantitatively over 25 min using high performance anion exchange chromatography with 100 µM UA‐4SGalNAc (Figure 4D). No reduction in substrate concentration is observed with whole cells or PBS controls while, cell lysates display a clear reduction in substrate concentration. These data confirm the cellular location of BT3349Δ4,5UA‐4SGalNAc but critically show that diffusion of sulfated sugars, tested here, across the B. theta outer membrane is not observable under aerobic conditions; even at high substrate concentrations. It should be noted that these experiments used B. theta cells that were centrifuged and washed three times with PBS whilst the MU‐β‐3S‐Gal/GalNAc based assays were performed in minimal media. The cells underwent no mechanical or osmotic stress which whilst of no consequence for B. theta is certainly not the case for all colonic bacteria [46] adding expanded utility to the substrates and methodology deployed here. These data indicate that MU‐β‐3S‐Gal (1) can be used as a broad tool for investigating the cellular location of S1_20 sulfatases from Bacteroidota cells directly from the media, and potentially other colonic microbiota species. Conclusions The lack of rapid, scalable assays for carbohydrate sulfatases has hindered our understanding of this important class of enzymes. Here, we have demonstrated the utility of coupled assays employing fluorogenic sulfated carbohydrate substrates to determine the catalytic properties, inhibition constants, and cellular location of S1 carbohydrate sulfatases. These assays have allowed us to quantify the substrate specificity and localization of mucin active sulfatases of B. theta, a key member of the human gut microbiome. Furthermore, we show that, using these tools, we can identify inhibitors for the sulfatase BT16363S‐Gal that is essential for the degradation of sulfated mucins by B. theta. We have also used x‐ray crystal structures of these bound inhibitors to rationalize their potency. Together, these results establish the power of the tools developed here for exploring and understanding the action of carbohydrate sulfatases. The assays disclosed here will be a starting point to develop techniques, including metagenomic enzyme discovery [47, 48, 49], directed evolution [50, 51], microbial phenotyping [52, 53] and in vivo imaging, that rely on robust and high‐throughput assays to enhance fundamental insight into sulfated carbohydrate metabolism. In addition, the synthesis of analogous chemical tools should facilitate the investigation of other sulfatases that currently lack sensitive or high‐throughput activity assays. This could be particularly interesting for the investigation of enzymes that desulfate glycosaminoglycans, glycolipids, N‐glycans and sulfated polysaccharides found in food, such as phorphyran [54, 55, 56]. We anticipate these tools will advance our understanding of carbohydrate sulfatases in host‐microbiome interactions and our search for molecules that can modulate these interactions. Author Contributions Charles W.E. Tomlinson: writing – review and editing, investigation, methodology, visualization.Madouc D. Bergers: investigation, visualization, methodology, writing – review and editing. David N. Bolam: resources. Ana S. Luis: resources. Alan Cartmell: conceptualization, funding acquisition, writing – original draft, writing – review and editing, visualization, resources, supervision. Zachary Armstrong: conceptualization, funding acquisition, writing – original draft, writing – review and editing, visualization, resources, supervision. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File 1: anie72868‐sup‐0001‐SuppMat.docx. Acknowledgments We thank the YSBL x‐ray Facility at the University of York (Rigaku Synergy Flow funded by the BBSRC (grant number BB/T017805/1)) for access and Dr Johan Turkenburg and Mr Sam Hart for assistance. The authors would like to thank Diamond Light Source for beamtime (proposal mx39189), and the staff of beamlines I03, and I04 for their assistance. The authors thank G.J. Davies for providing expression constructs for BVU_2198. Z.A. acknowledges the Dutch Research Council (NWO) for funding support (VI.Veni.212.173, OCENW.M.24.135). We also thank K. J. Rijpkema, for technical assistance and J.D.C. Codée for helpful discussions. Funding was provided to AC from the Academy of Medical Sciences/Wellcome Trust through the Springboard Grant (SBF005∖1065 163470), the Royal Society through their research grant (RGS∖R2∖212050), and a Wellcome Trust CDA (225897/Z/22/Z). Contributor Information Alan Cartmell, Email: alan.cartmell@york.ac.uk. Zachary Armstrong, Email: z.w.b.armstrong@lic.leidenuniv.nl. Data Availability Statement The data that support the findings of this study are openly available in Protein Data Bank at https://www.rcsb.org/, reference number 9THU, 9THV, and 9THW. References Associated Data Supplementary Materials Supporting File 1: anie72868‐sup‐0001‐SuppMat.docx. Data Availability Statement The data that support the findings of this study are openly available in Protein Data Bank at https://www.rcsb.org/, reference number 9THU, 9THV, and 9THW.